The European Patent Office (EPO) has granted patent EP3334765B1, titled "CHIMERIC ANTIGEN RECEPTORS BASED ON SINGLE-DOMAIN ANTIBODIES AND METHODS OF USE THEREOF." This patent, effective March 18, 2026, relates to advancements in CAR technology utilizing single-domain antibodies, a significant development in the field of cancer immunotherapy and biotechnology.

This patent grant signifies the EPO's recognition of novel intellectual property in the biotech sector. Companies operating in this space, particularly those involved in the development or application of CAR therapies, should be aware of this granted patent. While this is a patent grant and not a regulatory rule imposing direct compliance obligations, it establishes exclusive rights for the patent holder, potentially impacting research, development, and commercialization activities for others in the field.